Added to YB: 2025-07-11
Pitch date: 2025-05-23
RX.V [bullish]
BioSyent Inc.
+1.43%
current return
Author Info
No bio for this author
Company Info
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
Market Cap
CAD 132.8M
Pitch Price
CAD 11.85
Price Target
N/A
Dividend
1.69%
EV/EBITDA
10.88
P/E
17.68
EV/Sales
3.04
Sector
Pharmaceuticals
Category
growth
BioSyent Inc. - $RX.V
RX.V: Canadian pharma co with 59 consecutive profitable quarters, 15% annual returns, 42% Q1 YoY growth (record $11M). FeraMAX iron supplement (70% of rev, 18% growth) + Tibelia acquisition (1.3x sales, <5x EBITDA) diversifying revenue. 26% insider ownership, active buybacks. Trading at 14x trailing earnings ex-cash, ~7x 2026 EV/EBITDA. Risks: FeraMAX concentration, int'l execution.
Read full article (4 min)